TOP STORIES

• REGULATORY Japan Resumes Debate on Rx-to-OTC Switch of PPIs after Over 5 Years
  March 22, 2024

• BUSINESS Will Kyowa Kirin’s Eye Drops for nAMD Replace Intraocular Injections? PII Now Underway
  March 21, 2024

• BUSINESS Meiji’s Bivalent COVID Jab Hits Primary Goal in PIII Omicron Trial; New Strains Eyed
  March 21, 2024

• REGULATORY Japan Mulls Simplifying Drug Delisting Process to Help Ensure Stable Supplies
  March 19, 2024

• BUSINESS FY2024 Revision Rates Tallied for Each Firm’s Top 5 Meds; Fuso Logs Price Hike Too on Infusion Products
  March 18, 2024

• BUSINESS Sumitomo Offloads Entire Ulotaront Rights to Otsuka for Strategic Priorities
  March 18, 2024

• REGULATORY Japan to Present Class-by-Class Generic Shares to Hit New Goals: Minister
  March 18, 2024

• REGULATORY Japan Begins Discussions on RSV Vaccines for National Immunization Program
  March 15, 2024

• BUSINESS Takeda Settles on Lower Pay Hike than 2023; Union Group Says Pharma Labor Talks Tougher than Others
  March 15, 2024

• REGULATORY PD-1/PD-L1, JAK Drugs to Be Exempt from Spillover Price Cuts: Chuikyo
  March 14, 2024

• REGULATORY Lagevrio, Kerendia Braced for Price Cuts after Cost-Effectiveness Assessment
  March 14, 2024

• REGULATORY Japan Needs Systemic Reform to Balance Universal Coverage and Access to Pricey Meds: LDP Health Affairs Chief
  March 13, 2024

• COMMENTARY With So Many of Its Demands Met, How Will Industry Oppose Off-Year Price Revisions in FY2025?
  March 12, 2024

• REGULATORY PMDA Looks to Rev Up Pediatric and Orphan Drug Initiatives in Next 5-Year Plan: Chief
  March 11, 2024

• ACADEMIA Expert Says RSV Shots Will Have Significant Clinical Impact, Urges Public Funding and NIP Inclusion
  March 8, 2024

• BUSINESS Eisai CEO Confident in Leqembi Uptake, Says 90% of US Hospital Targets to Adopt Med by March-End
  March 8, 2024

• BUSINESS Majority of Drug Makers “Somewhat Satisfied” with FY2024 Revision: Poll
  March 7, 2024

• BUSINESS Removal of PMP Company Indicators Most Popular Policy Change in FY2024 Reform: Poll
  March 7, 2024

• BUSINESS Tsumura Sees 24% Price Hike as Kampo Enjoys Boon in FY2024 Revision: Poll
  March 6, 2024

• REGULATORY Opdivo Faces 15% Slash in Spillover, Re-Pricing to Hit 23 Drugs in FY2024 Revision
  March 5, 2024

ページ

• « 先頭
• ‹ Prev
• …
• 33
• 34
• 35
• 36
• 37
• 38
• 39
• 40
• 41
• …
• Next ›
• 最終 »